['advanced solid tumors']
['linsitinib', 'erlotinib', 'paclitaxel', 'bortezomib', 'dexamethasone']

        Inclusion Criteria:

          -  Subject must currently be participating in an Astellas sponsored linsitinib trial that
             has ended with respect to the overall study analysis.

          -  Subject must not have met criteria for discontinuation or have progressed on the
             current linsitinib study in which they are participating.

          -  Subject must be deriving benefit from continued treatment.
      